Dr. Alexei Shimanovsky, MD

Dr. Shimanovsky practices at UMass Memorial Health - Milford Regional Medical Center in Milford, Massachusetts, part of UMass Memorial Health Care.

Dr. Shimanovsky's NPI, 1699054924, was assigned on August 4, 2011. Dr. Shimanovsky holds Massachusetts license 1015150.

Dr. Shimanovsky's primary practice is UMass Memorial Health - Milford Regional Medical Center, at 14 Prospect Street, Milford, MA 01757 in Worcester County. The practice phone is (508) 473-1190.

Dr. Shimanovsky's primary practice is UMass Memorial Health - Milford Regional Medical Center in Milford, Massachusetts, part of UMass Memorial Health Care. Dr. Shimanovsky is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Shimanovsky to 2 more hospitals and 1 imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shimanovsky practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Shimanovsky's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Shimanovsky's licenses on file in 2 states: Massachusetts and Rhode Island.

CMS data shows 741 Medicare services from Dr. Shimanovsky across 6 procedure codes in 2024, for 190 Medicare patients. Medicare paid $65,055 for them.

CMS counts 190 Medicare patients who saw Dr. Shimanovsky in 2024. The largest group is 65 to 74, with 78 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shimanovsky's median patient age at 67, with 45% women.

In 2024, Dr. Shimanovsky wrote 708 Medicare Part D claims for 135 patients. 87% of them were for generic drugs. CMS names the drug for 525 of them, across 20 drugs with 11 or more claims each, at $33,516 in total drug cost. In 2023, CMS named 184 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Shimanovsky for performance year 2024, reported as part of a group. Dr. Shimanovsky accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shimanovsky as offering telehealth.

Dmand AI links 12 papers to Dr. Shimanovsky, published from 2013 to 2021. 2013 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols. Dr. Shimanovsky has published most often in BMJ Case Rep. Dr. Shimanovsky's most frequent co-authors are Constantin Dasanu, MD, PhD, Juliana Alvarez Argote, MD and William Jeffrey Baker, MD.

CMS Open Payments shows 9 general payments to Dr. Shimanovsky from 6 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 78% of the total. Genentech, Inc. paid the most, $293.